Global Clostridium Difficile Infection Drugs Market, By Drugs (Metronidazole, Vancomycin, Fidaxomicin, Metronidazole, Probiotics, Others), Route of Administration (Oral, Parenteral, Others), End-Users (Hospitals, Specialty Clinics, Home Healthcare, Others), Distribution Channel (Hospital Pharmacy, Retail Pharmacy, Online Pharmacy, Others) - Industry Trends and Forecast to 2030.
Clostridium Difficile Infection Drugs Market Analysis and Size
Growing cases of diarrhea and nosocomial diseases drive the clostridium difficile infections market due to environmental pollution, unhygienic conditions, and consumption of processed meat which causes C. difficile infection also boosts up the clostridium difficile infections market growth. However, novel antibiotics positioned to reduce the incidence rate of disease recurrence relative to standard care and advanced microbiological technology for the diagnosis will boost up the global clostridium difficile infections market. But lack of patient awareness may hamper the global clostridium difficile infections market.
Data Bridge Market Research analyzes that the global clostridium difficile infection drugs market which was USD 8.58 billion in 2022, would rocket up to USD 13.92 billion by 2030, and is expected to undergo a CAGR of 7.0% during the forecast period 2023 to 2030. This indicates the market value. “Metronidazole” dominates the drug segment of the global clostridium difficile infection drugs market owing to the surge in the number of people suffering from clostridium difficile infection. In addition to the insights on market scenarios such as market value, growth rate, segmentation, geographical coverage, and major players, the market reports curated by the Data Bridge Market Research also include depth expert analysis, patient epidemiology, pipeline analysis, pricing analysis, and regulatory framework.
Clostridium Difficile Infection Drugs Market Scope and Segmentation
|
Report Metric
|
Details
|
|
Forecast Period
|
2023 to 2030
|
|
Base Year
|
2022
|
|
Historic Year
|
2021 (Customizable to 2015-2020)
|
|
Quantitative Units
|
Revenue in USD Billion, Volumes in Units, Pricing in USD
|
|
Segments Covered
|
Drugs (Metronidazole, Vancomycin, Fidaxomicin, Metronidazole, Probiotics, Others), Route of Administration (Oral, Parenteral, Others), End-Users (Hospitals, Specialty Clinics, Home Healthcare, Others), Distribution Channel (Hospital Pharmacy, Retail Pharmacy, Online Pharmacy, Others)
|
|
Countries Covered
|
U.S., Canada, Mexico, Germany, Italy, U.K., France, Spain, Netherland, Belgium, Switzerland, Turkey, Russia, Rest of Europe, Japan, China, India, South Korea, Australia, Singapore, Malaysia, Thailand, Indonesia, Philippines, Rest of Asia- Pacific, Brazil, Argentina, Rest of South America, South Africa, Saudi Arabia, UAE, Egypt, Israel, Rest of Middle East & Africa
|
|
Market Players Covered
|
Novartis AG (Switzerland), Baxter (US), ANI Pharmaceuticals Inc. (US), Mylan N.V. (US), Akorn (US), Sun Pharmaceutical Industries Ltd.(India), Merck & Co., Inc. (US), B. Braun Medical Inc. (US), Teva Pharmaceutical Industries Ltd. (Israel), Hikma Pharmaceutical PLC (UK), Perrigo Pharmaceutical. (India), Apotex Inc. (Canada), AbbVie Inc.(US), Fresenius Kabi USA (US)., Pfizer Inc.(US), Strides Pharma Science Limited. (India), Sanofi. (France), AstraZeneca. (UK), Eli Lilly and Company. (US), Actelion Pharmaceuticals Ltd. (Switzerland), Astellas Pharma. (Japan) among other.
|
|
Market Opportunities
|
|
Market Definition
Clostridium difficile, also known as clostridioides difficile and usually referred to as C. difficile or C. diff. Clostridium difficile is a gram-positive, fastidiously anaerobic bacillus that can cause symptoms to range from mild to severe diarrhea to life-threatening inflammation of the colon. The main causes of Clostridium difficile are unhygienic environmental conditions because it is found in soil, water, human and animal stools, processed meat and food products. Spores of Clostridium difficile are passed in feces and spread to food, surface and object. When anybody touches the infected object, unknowingly swallow the bacteria. The symptoms of watery diarrhea, mild abdominal cramping and tenderness, rapid heart rate, nausea, dehydration, swollen abdomen and kidney failure if not treated on time. A new strain of clostridium difficile may be more resistant to certain medications and can cause a serious outbreak.
Global Clostridium Difficile Infection Drugs Market Dynamics
Drivers
Increasing Awareness and Diagnosis
As medical knowledge and awareness of clostridium difficile infection continue to grow, there may be an increase in the diagnosis and recognition of the condition. This can lead to a higher demand for diagnostic tools, treatments, and research related to clostridium difficile infection.
Prolonged Consumption of Antibiotics
Consumption changes the normal colon bacteria, and that allows the growth of the Clostridium difficile bacteria. The antibiotics which are at higher risk of growing clostridium difficile infection (CDI) are cephalosporins, clindamycin, and quinolones such as ciprofloxacin and levofloxacin. Increasing usage of these antimicrobials and antibiotics is fuelling incidences of clostridium difficile infection and is likely to boost the adoption of its treatments.
Opportunities
Development of innovative therapies and treatment approaches
Most clostridium difficile infection treatments focus on managing symptoms and slowing the progression of the disease. However, there is a significant need for new and innovative therapies that provides better outcomes for patients and improve their quality of life. In recent years, research and development have focused on new clostridium difficile infection treatments, including biologics, gene therapies, and other novel approaches. These therapies potentially address the underlying causes of clostridium difficile infection and provide patients with more effective and targeted treatment options.
Restraints/Challenges
High cost of treatment:
Clostridium difficile infection is a chronic disease that often requires long-term care and specialized treatment, which is expensive. In addition, many clostridium difficile infection patients also have other comorbidities, which further increase healthcare costs. The cost of clostridium difficile infection treatment is a major barrier to access for many patients, particularly in developing countries with high healthcare costs and limited insurance coverage. This leads to underdiagnosis and undertreatment of the disease, negatively impacting patient outcomes and quality of life.
Recent Developments
- In November 2022, Ferring Pharmaceuticals announced that the FDA had approved REBYOTA® (fecal microbiota, live-jslm), a novel first-in-class microbiota-based live biotherapeutic indicated for the prevention of recurrence of Clostridioides difficile infection (CDI) in individuals 18 years of age and older, following antibiotic treatment for recurrent CDI.
- In November 2022, Ferring Pharmaceuticals announced the publication of its pivotal Phase III PUNCHTM CD3 clinical trial data in the journal Drugs, in which a single dose of RBX2660 outperformed placebo in a Bayesian analysis model to reduce the recurrence of Clostridioides difficile infection (CDI) after standard-of-care antibiotic treatment.
Global Clostridium Difficile Infection Drugs Market Scope
The global clostridium difficile infection drugs market is segmented on the basis of drugs, route of administration, end-users and distribution channel. The growth amongst these segments will help you analyze meager growth segments in the industries and provide the users with a valuable market overview and market insights to help them make strategic decisions for identifying core market applications.
Drugs
- Metronidazole
- Vancomycin
- Fidaxomicin
- Metronidazole
- Probiotics
- Others
Route of Administration
- Oral,
- Parenteral
- Others
End User
- Hospitals
- Speciality Clinics
- Others
Distribution Channel
- Hospital Pharmacy
- Retail Pharmacy
- Online Pharmacy
- Others
Global Clostridium Difficile Infection Drugs Market Regional Analysis/Insights
The global clostridium difficile infection drugs market is analyzed, and market size insights and trends are provided by country, drugs, route of administration, end user and distribution channel as referenced above.
The countries covered in the global clostridium difficile infection drugs market report are the U.S., Canada, Mexico, Peru, Brazil, Argentina, Rest of South America, Germany, Italy, U.K., France, Spain, Netherlands, Belgium, Switzerland, Turkey, Russia, Hungary, Lithuania, Austria, Ireland, Norway, Poland, Rest of Europe, Japan, China, India, South Korea, Australia, Singapore, Malaysia, Thailand, Indonesia, Philippines, Vietnam, Rest of Asia Pacific, South Africa, Saudi Arabia, U.A.E, Kuwait, Israel, Egypt, Rest of Middle East and Africa.
North America is expected to dominate the global clostridium difficile infection drugs market because of the strong base of healthcare facilities, the strong presence of major players in the market, the increasing cases of clostridium difficile infection and rising number of research activities in this region.
Asia-Pacific is expected to witness significant growth during the forecast period of 2023 to 2030 due to the increase in government initiatives to promote awareness, growing research activities in the region, availability of massive untapped markets, a large population pool, and the growing demand for quality healthcare in the region.
The country section of the report also provides individual market-impacting factors and changes in regulation in the market domestically that impact the current and future trends of the market. Data points like downstream and upstream value chain analysis, technical trends, Porter's five forces analysis, and case studies are some of the pointers used to forecast the market scenario for individual countries. Also, the presence and availability of global brands and their challenges faced due to large or scarce competition from local and domestic brands, the impact of domestic tariffs, and trade routes are considered while providing forecast analysis of the country data.
Healthcare Infrastructure Growth Installed Base and New Technology Penetration
The global clostridium difficile infection drugs market also provides you with a detailed market analysis for every country's growth in healthcare expenditure for capital equipment, installed base of different kinds of products for the global clostridium difficile infection drugs market, the impact of technology using lifeline curves and changes in healthcare regulatory scenarios and their impact on the global clostridium difficile infection drugs market. The data is available for the historic period 2015-2020.
Competitive Landscape and Global Clostridium Difficile Infection Drugs Market Share Analysis
The global clostridium difficile infection drugs market competitive landscape provides details of competitors. Details included are company overview, company financials, revenue generated, market potential, investment in research and development, new market initiatives, global presence, production sites and facilities, production capacities, company strengths and weaknesses, product launch, product width and breadth, and application dominance. The above data points provided are only related to the companies' focus related to the market.
Some of the major players operating in the global clostridium difficile infection drugs market are:
- Novartis AG (Switzerland)
- Baxter (US)
- ANI Pharmaceuticals Inc. (US)
- Mylan N.V. (US)
- Akorn (US)
- Sun Pharmaceutical Industries Ltd.(India)
- Merck & Co., Inc. (US)
- B. Braun Medical Inc. (US)
- Teva Pharmaceutical Industries Ltd. (Israel)
- Hikma Pharmaceutical PLC (UK)
- Perrigo Pharmaceutical. (India)
- Apotex Inc. (Canada)
- AbbVie Inc.(US)
- Fresenius Kabi USA (US)
- Pfizer Inc.(US)
- Strides Pharma Science Limited. (India)
- Sanofi. (France)
- AstraZeneca. (UK)
- Eli Lilly and Company. (US)
- Actelion Pharmaceuticals Ltd. (Switzerland)
- Astellas Pharma. (Japan)
SKU-